Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The precision, or personalized, medicine movement predicts a future of patient care informed by measurable genetic, environmental, and behavioral characteristics unique to the individual patient.1 Implicit in this approach is the availability of biomarkers, including genetic variants, that accurately predict important health outcomes. Over the last decade, genome-wide association studies (GWAS) have identified hundreds of new genetic variations, largely single-nucleotide polymorphisms (SNPs) that might serve as biomarkers for many common conditions. In general, these account for little in the variance of disease, and the predictive value of such SNPs has been largely disappointing.2,3
Feero WG. Establishing the Clinical Validity of Arrhythmia-Related Genetic Variations Using the Electronic Medical RecordA Valid Take on Precision Medicine?. JAMA. 2016;315(1):. doi:10.1001/jama.2015.17702